Curcumin as possible maintenance therapy: Phase II study at MD Anderson, June 2011

I read a Google Alert early this morning that made me think I was still asleep and dreaming…

In June 2011, a randomized, double-blind efficacy study is set to begin at the M.D. Anderson Cancer Research Center in Houston, Texas. Completion date: June 2014. Chief investigator: Robert Orlowski, MD, Ph.D.

Excerpt: The goal of this clinical research study is to learn if curcumin can reduce the symptoms reported by patients with multiple myeloma (MM) who receive treatment with lenalidomide. As you can read in the post title, this is a maintenance therapy study. In addition to a 5-15 mg daily dose of lenalidomide, each patient will receive eight grams of curcumin…or, of course, a placebo, administered in the same way as curcumin.

Here is the direct link to the Clinical Trial information: 

I have so many questions, which will probably remain unanswered for quite some time, such as: which type of curcumin will these patients be taking? The C3 Complex curcumin or another type? Will the curcumin/placebo be divided into different doses (that would be my guess…) and, if so, how many? Will the curcumin/placebo be taken with food or on an empty stomach? Together with lenalidomide or not?

Well, this is a very VERY (VERY!!!) exciting bit of news, I must say! Yes indeedie!

1 Comment

  1. Hi Margaret,
    I’ve been reading your blog for a few months now. I was dx in March of last year and just had a sct. Started taking the curcumin in January and have been reading lots of older posts. One thing that I noted with interest though is the “study has been withdrawn prior to enrollment”. So it seems like they aren’t doing it for some reason which is too bad. Do you know anything about it?


Leave a Reply

Your email address will not be published. Required fields are marked *